Nepafenac

Generic Name: Nepafenac

Brand Names: Ilevro, Nevanac

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O_₂

CAS Number: 78281-72-8

Unique Ingredient Identifier: 0J9L7J6V8C

Background: Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Indication: For the treatment of pain and inflammation associated with cataract surgery.

Associated Conditions: Inflammation, Pain

Clinical Trials

Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)

Phase 4

Recruiting

Conditions: Cataract Surgery

Interventions: Drug: Nepafenac Ophthalmic
Drug: Dexamethasone Ophthalmic

First Posted Date: 2022-04-18

Last Posted Date: 2022-12-01

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 500

Registration Number: NCT05331690

Locations: 🇳🇴
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)

Phase 4

Recruiting

Conditions: Descemet Membrane Endothelial Keratoplasty (DMEK)
Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)

Interventions: Drug: Nepafenac Ophthalmic
Drug: Dexamethasone Ophthalmic

First Posted Date: 2021-10-08

Last Posted Date: 2022-12-01

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 300

Registration Number: NCT05072262

Locations: 🇳🇴
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

Phase 2

Conditions: Congenital Hereditary Endothelial Dystrophy of Cornea

Interventions: Drug: Refresh Tears 0.5% Lubricant Eye Drops
Drug: Nepafenac 0.1% Oph Susp

First Posted Date: 2021-04-14

Last Posted Date: 2021-04-14

Lead Sponsor: L.V. Prasad Eye Institute

Target Recruit Count: 30

Registration Number: NCT04843839

Locations: 🇮🇳
L V Prasad Eye Institute, Hyderabad, Banjara Hills, India

Post Intravitreal Injection Topical NSAID vs. Patching

Phase 4

Conditions: Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion

Interventions: Drug: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
Other: patching
Drug: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)

First Posted Date: 2019-04-17

Last Posted Date: 2019-04-17

Lead Sponsor: The New York Eye & Ear Infirmary

Target Recruit Count: 60

Registration Number: NCT03918590

Locations: 🇺🇸
New York Eye and Ear Infirmary, New York, New York, United States

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Phase 4

Completed

Conditions: Treatment of Ocular Inflammation Associated With Cataract Surgery

Interventions: Drug: Nepafenac
Drug: Bromfenac

First Posted Date: 2019-03-22

Last Posted Date: 2019-04-01

Lead Sponsor: Silverstein Eye Centers

Target Recruit Count: 57

Registration Number: NCT03886779

Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery

Phase 2

Conditions: Cataract
Miosis

Interventions: Drug: Nepafenac Ophthalmic
Drug: Ketorolac Ophthalmic
Drug: Cyclopentolate Ophthalmic

First Posted Date: 2019-02-22

Last Posted Date: 2019-02-25

Lead Sponsor: Assiut University

Target Recruit Count: 75

Registration Number: NCT03851172

PGE2 Levels in Patient Treated With NSAIDs

Phase 3

Completed

Conditions: Ocular Inflammation

Interventions: Drug: Indom
Other: Placebo
Drug: Dicloftil
Drug: Nevanac
Drug: Yellox

First Posted Date: 2018-07-24

Last Posted Date: 2018-07-24

Lead Sponsor: University of Trieste

Target Recruit Count: 104

Registration Number: NCT03597867

Locations: 🇮🇹
Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Placebos
Drug: Nepafenac 0.3% Oph Susp
Drug: Nepafenac 0.3% Oph Susp (reference)

First Posted Date: 2018-04-17

Last Posted Date: 2021-02-16

Lead Sponsor: Actavis Inc.

Target Recruit Count: 448

Registration Number: NCT03499873

Locations: 🇺🇸
Key-Whitman Eye Center, Dallas, Texas, United States

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: Artificial tear
Drug: Nepafenac 0.1% Oph Susp
Drug: Nepafenac 0.3% Oph Susp

First Posted Date: 2018-01-23

Last Posted Date: 2018-04-04

Lead Sponsor: University Hospital of Patras

Target Recruit Count: 99

Registration Number: NCT03406689

Locations: 🇬🇷
University Hospital of Patras, Patra, Achaia, Greece

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Not Applicable

Completed

Conditions: Cystoid Macular Edema

Interventions: Drug: Nepafenac 0.3%
Drug: Saline Solution

First Posted Date: 2017-01-20

Last Posted Date: 2018-12-14

Lead Sponsor: Intuor Technologies, Inc.

Target Recruit Count: 662

Registration Number: NCT03025945

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy